All PKI-based drugs marketed today are intended for the treatment of patients with different forms of cancer. Only one PKI product (Xeljanz, tofacitinib) is indicated for the treatment of patients with rheumatoid arthritis.
Original products for two of Xspray’s product candidates, HyNap-Nilo (Tasigna) and HyNap-Dasa (Sprycel), are indicated for the treatment of adult patients with chronic phase chronic myeloid leukemia (ChML) newly diagnosed Philadelphia.
Sprycel is also indicated for the treatment of adult patients with Ph + acute lymphocytic leukemia (ALL) and lymphoid blastic CML with resistance or intolerance to prior treatment. The original product of HyNap-Sora, Nexavar, is intended for the treatment of patients with liver cell cancer, renal cell cancer and differentiated thyroid cancer.